Cure8 trial brief
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this combination is safe and effective when used alongside routine vedolizumab care.
Adults with moderately to severely active ulcerative colitis; patients already prescribed vedolizumab or considering vedolizumab; IBD clinicians and clinical researchers.
This is a registered randomized, double-blind, placebo-controlled Phase 4 trial (not yet recruiting) testing whether adding an oral combination product called CurQD (curcumin + QingDai) to standard-of-care vedolizumab improves outcomes for adults with moderately to severely active ulcerative colitis.
The planned study is 30 weeks long with a primary endpoint of clinical remission at week 14 as measured by a modified Mayo score; vedolizumab is given per the participant’s treating clinician and CurQD (or matching placebo) is taken orally in escalating doses.
The trial excludes people with prior vedolizumab exposure, recent severe/fulminant disease, many serious comorbidities (eg, significant liver or renal disease, untreated infections, pregnancy), and those on multiple other advanced therapies. About 160 participants are planned and the lead site listed is Mount Sinai (New York).
If you are considering participation, discuss with your GI team whether you meet the trial’s specific eligibility rules and whether concomitant therapies you take are allowed. The registry entry describes interventions and key inclusion/exclusion criteria but does not report results.
This is a trial record (Phase 4) that is not yet recruiting and does not contain results. CurQD is a combination of curcumin and QingDai supplied in capsule form; the registry lists planned dosing ranges. The entry should be interpreted as a study plan—no efficacy or safety findings are reported here.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
